Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Autoimmune hepatitis (AIH) is a chronic disease that may lead to cirrhosis. The immunopathogenesis of AIH is not fully understood and it mainly involves T-cell mediated mechanism. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that promotes T cell response and its polymorphism may serve as a severity marker of AIH. No previous study has considered investigating MIF polymorphism in children with AIH. Methods: Forty-two children with definite diagnosis of AIH were enrolled along with 100 age and sex matched controls. All participants were tested for polymorphism at -173GC (rs755622) of MIF gene. All patients received the standard protocol of steroid plus azathioprine to achieve remission. Liver biopsy was performed at time of diagnosis for all patients and only 18 of them underwent a second biopsy after treatment. Results: No statistically significant differences in the frequency of the genotypes GG and GC or in allele distribution were found in both patient and control groups (p=0.590, 0.640 respectively). Initial alanine aminotransferase (ALT) levels at the time of presentation was significantly higher in the GC group than GG group (p=0.020). GC genotype significantly correlated with disease relapse (r=0.41, p=0.007). Regression of necroinflammation and the fibrosis score in the second liver biopsy was statistically significant in the GG group (p<0.0001, p=0.010 respectively). Conclusion: MIF -173GC polymorphism is associated with clinically significant markers of pediatric AIH, including increased initial serum ALT levels, may help predict necroinflammatory/fibrosis regression effectively, following immunosuppressive treatment.
Abstract
Purpose: Autoimmune hepatitis (AIH) is a chronic disease that may lead to cirrhosis. The immunopathogenesis of AIH is not fully understood and it mainly involves T-cell mediated mechanism. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that promotes T cell response and its polymorphism may serve as a severity marker of AIH. No previous study has considered investigating MIF polymorphism in children with AIH. Methods: Forty-two children with definite diagnosis of AIH were enrolled along with 100 age and sex matched controls. All participants were tested for polymorphism at -173GC (rs755622) of MIF gene. All patients received the standard protocol of steroid plus azathioprine to achieve remission. Liver biopsy was performed at time of diagnosis for all patients and only 18 of them underwent a second biopsy after treatment. Results: No statistically significant differences in the frequency of the genotypes GG and GC or in allele distribution were found in both patient and control groups (p=0.590, 0.640 respectively). Initial alanine aminotransferase (ALT) levels at the time of presentation was significantly higher in the GC group than GG group (p=0.020). GC genotype significantly correlated with disease relapse (r=0.41, p=0.007). Regression of necroinflammation and the fibrosis score in the second liver biopsy was statistically significant in the GG group (p<0.0001, p=0.010 respectively). Conclusion: MIF -173GC polymorphism is associated with clinically significant markers of pediatric AIH, including increased initial serum ALT levels, may help predict necroinflammatory/fibrosis regression effectively, following immunosuppressive treatment.
참고문헌 (30)
- Maggiore G, "Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents", J Pediatr Gastroenterol Nutr, 17, pp.376~381 (1993)
- Mieli-Vergani G, "Autoimmune hepatitis", J Pediatr Gastroenterol Nutr, 49, pp.158~164 (2009)
- Gregorio GV, "Autoimmune hepatitis in childhood : a 20-year experience", Hepatology, 25, pp.541~547 (1997)
- Mieli-Vergani G, "Autoimmune paediatric liver disease", World J Gastroenterol, 14, pp.3360~3367 (2008)
- Czaja AJ, "Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis : a retrospective analysis", Hepatology, 35, pp.890~897 (2002)
- Czaja AJ, "Difficult treatment decisions in autoimmune hepatitis", World J Gastroenterol, 16, pp.934~947 (2010)
- de Boer YS, "Genome-wide association study identifies variants associated with autoimmune hepatitis type 1", Gastroenterology, 147, pp.443~452 (2014)
- Czaja AJ, "Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis", Gastroenterology, 139, pp.58~72 (2010)
- Vergani D, "Aetiopathogenesis of autoimmune hepatitis", World J Gastroenterol, 14, pp.3306~3312 (2008)
- Calandra T, "MIF as a glucocorticoid-induced modulator of cytokine production", Nature, 377, pp.68~71 (1995)
- Bucala R. MIF, "and prospects for therapeutic intervention in autoimmunity", J Clin Immunol, 33(Suppl 1), pp.S72~78 (2013)
- Assis DN, "The role of macrophage migration inhibitory factor in autoimmune liver disease", Hepatology, 59, pp.580~591 (2014)
- Assis DN, "A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients", Dig Dis Sci, 61, pp.3506~3512 (2016)
- Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
- Roberts S, "Macrophage migration inhibitory factor(MIF)modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease", J Hepatol, 66, pp.S363~4 (2017)
- Sreih A, "Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus", Arthritis Rheum, 63, pp.3942~3951 (2011)
- Foote A, "Macrophage migration inhibitory factor in systemic lupus erythematosus", J Rheumatol, 31, pp.268~273 (2004)
- Llamas-Covarrubias MA, "Macrophage migration inhibitory factor(MIF) : genetic evidence for participation in early onset and early stage rheumatoid arthritis", Cytokine, 61, pp.759~765 (2013)
- Zhang H, "Association of the macrophage migration inhibitory factor gene--173G", C polymorphism with inflammatory bowel disease : a meta-analysis of 4296 subjects, 2013, pp.526, 228~231
- Berdeli A, "Association of macrophage migration inhibitory factor-173C allele polymorphism with steroid resistance in children with nephrotic syndrome", Pediatr Nephrol, 20, pp.1566~1571 (2005)
- Arikan C, "Positive association of macrophage migration inhibitory factor gene-173G", C polymorphism with biliary atresia, 2006, pp.42, 77~82
- Sadek KH, "Macrophage migration inhibitory factor(MIF)gene promotor polymorphism is associated with increased fibrosis in biliary atresia patients, but not with disease susceptibility", Ann Hum Genet, 81, pp.177~183 (2017)
- Akyildiz M, "Macrophage migration inhibitory factor expression and MIF gene-173 G", C polymorphism in nonalcoholic fatty liver disease, 2010, pp.22, 192~198
- Moudi B, "Gene polymorphisms of macrophage migration inhibitory factor affect susceptibility to chronic hepatitis B virus infection in an Iranian cohort", Microbiol Immunol, 60, pp.390~396 (2016)
- Zhang HY, "Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection", Liver Int, 25, pp.571~579 (2005)
- Zhang K, "Relationship between MIF-173 G", C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver cirrhosis, 2013, pp.282, 113~116
- Bahgat DMR, "Non-significant influence of macrophage migration inhibitory factor(MIF)promoter gene polymorphisms on the risk or activity of Egyptian Behçet’s disease patients : potential role of MIF+254T", C in posterior uveitis, 2017, pp.39, 115~120
- El-Edel RH, "Association of macrophage migration inhibitory factor-173G", C polymorphism with dilated cardiomyopathy in children, 2018, pp.31, 306~310
- Radstake TR, "Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor", Arthritis Rheum, 52, pp.3020~3029 (2005)